Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 43; pp. 159 - 447 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2/10/2025 Supplement5
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184084393&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 184084393 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2/10/2025 Supplement5 vid: 43 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 184084393 10.1200/JCO.2025.43.5_suppl.159 184084393 ppf: 159 ppct: 288 formats: tig: atl: Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis. aug: au: Freedland, Stephen J. Gleave, Martin De Giorgi, Ugo Rannikko, Antti Sridharan, Swetha Brasso, Klaus Woo, Henry H. Gómez Caamaño, Antonio Nordquist, Luke Tang, Yiyun Croitoru, Ruslan Rosales, Matt Kalac, Matko Peraud, Olivier Wang, Fong Shore, Neal D. affil: Department of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|